Tobu M - Search Results

1

Anti-Xa and anti-IIa drugs alter international normalized ratio measurements: potential problems in the monitoring of oral anticoagulants.

Tobu M, Iqbal O, Hoppensteadt D, Neville B, Messmore HL, Fareed J. Tobu M, et al. Clin Appl Thromb Hemost. 2004 Oct;10(4):301-9. doi: 10.1177/107602960401000402. Clin Appl Thromb Hemost. 2004. PMID: 15497016 Free article.

2

Effects of a synthetic factor Xa inhibitor (JTV-803) on various laboratory tests.

Tobu M, Iqbal O, Hoppensteadt DA, Shultz C, Jeske W, Fareed J. Tobu M, et al. Clin Appl Thromb Hemost. 2002 Oct;8(4):325-36. doi: 10.1177/107602960200800404. Clin Appl Thromb Hemost. 2002. PMID: 12516682 Free article.

3

Global anticoagulant effects of a synthetic anti-factor Xa inhibitor (DX-9065a): implications for interventional use.

Tobu M, Iqbal O, Ma Q, Schultz C, Jeske W, Hoppensteadt D, Lewis B, Fareed D, Fareed J. Tobu M, et al. Clin Appl Thromb Hemost. 2003 Jan;9(1):1-17. doi: 10.1177/107602960300900101. Clin Appl Thromb Hemost. 2003. PMID: 12643318 Free article.

4

Erythropoietin-induced thrombosis as a result of increased inflammation and thrombin activatable fibrinolytic inhibitor.

Tobu M, Iqbal O, Fareed D, Chatha M, Hoppensteadt D, Bansal V, Fareed J. Tobu M, et al. Clin Appl Thromb Hemost. 2004 Jul;10(3):225-32. doi: 10.1177/107602960401000304. Clin Appl Thromb Hemost. 2004. PMID: 15247979 Free article.

5

Tissue factor pathway inhibitor and thrombin activatable fibrinolytic inhibitor plasma levels following burn and septic injuries in rats.

Ravindranath TM, Goto M, Demir M, Tobu M, Kujawski MF, Hoppensteadt D, Samonte V, Iqbal O, Sayeed MM, Fareed J. Ravindranath TM, et al. Among authors: tobu m. Clin Appl Thromb Hemost. 2004 Oct;10(4):379-85. doi: 10.1177/107602960401000411. Clin Appl Thromb Hemost. 2004. PMID: 15497025 Free article.

6

Antithrombotic agents in the treatment of severe sepsis.

Iqbal O, Messmore H, Fareed J, Ahmad S, Hoppensteadt D, Hazar S, Tobu M, Aziz S, Wehrmacher W. Iqbal O, et al. Among authors: tobu m. Expert Opin Emerg Drugs. 2002 May;7(1):111-39. doi: 10.1517/14728214.7.1.111. Expert Opin Emerg Drugs. 2002. PMID: 15989540

7

Molecular weight dependent tissue factor pathway inhibitor release by heparin and heparin oligosaccharides.

Ma Q, Tobu M, Schultz C, Jeske W, Hoppensteadt D, Walenga J, Cornelli U, Lee J, Linhardt R, Hanin I, Fareed J. Ma Q, et al. Among authors: tobu m. Thromb Res. 2007;119(5):653-61. doi: 10.1016/j.thromres.2006.05.007. Epub 2006 Jul 7. Thromb Res. 2007. PMID: 16824584 Free PMC article.

8

Air travel-associated venous thromboembolism.

Iqbal O, Eklof B, Tobu M, Fareed J. Iqbal O, et al. Among authors: tobu m. Med Princ Pract. 2003 Apr-Jun;12(2):73-80. doi: 10.1159/000069121. Med Princ Pract. 2003. PMID: 12634460 Free article. Review.

9

The Role of Thrombolytic Drugs in the Management of Acute Myocardial Infarction and Stroke.

Iqbal O, Tobu M, Demir M, Fareed J, Aziz S, Messmore H. Iqbal O, et al. Among authors: tobu m. Turk J Haematol. 2002 Jun 5;19(2):151-77. Turk J Haematol. 2002. PMID: 27264756 No abstract available.

10

Antithrombotic Agents in the Management of Sepsis.

Iqbal O, Tobu M, Hoppenstead D, Aziz S, Messmore H, Fareed J. Iqbal O, et al. Among authors: tobu m. Turk J Haematol. 2002 Sep 5;19(3):349-89. Turk J Haematol. 2002. PMID: 27264974

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

44 results

Search Page